NCT04649541View on ClinicalTrials.gov

Study of the Safety, Tolerability, and PK of MRX-8 Administered Intravenously to HVs in SAD and MAD Cohorts

PHASE1CompletedINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

November 29, 2020

Primary Completion Date

December 1, 2021

Study Completion Date

December 1, 2021

Conditions
Safety
Interventions
DRUG

MRX-8

novel semi-synthetic polymyxin B analog.

DRUG

Placebo

5% dextrose in water

Trial Locations (1)

85283

Celerion, Tempe

Sponsors

Lead Sponsor

MicuRx
All Listed Sponsors
collaborator

Biomedical Advanced Research and Development Authority

FED

collaborator

Wellcome Trust

OTHER

lead

MicuRx

INDUSTRY

NCT04649541 - Study of the Safety, Tolerability, and PK of MRX-8 Administered Intravenously to HVs in SAD and MAD Cohorts | Biotech Hunter | Biotech Hunter